Search research articles
Contact Us
Filters
Showing results (11-20 of 67) with videos related to
Page
of 7
Sort By:
Trends in Pharmacological Sciences
|
October 26, 2005
Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis
Jean-Michel Dogné, Julien Hanson, Domenico Pratico
Future Medicinal Chemistry
|
May 10, 2022
Super-conserved receptors expressed in the brain: biology and medicinal chemistry efforts
Alp Bayrak, Julien Hanson, Stefan Laufer, et al.
Trends in Pharmacological Sciences
|
September 28, 2011
Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials
Martina Lukasova, Julien Hanson, Sorin Tunaru, et al.
Pharmacology & Therapeutics
|
January 26, 2016
Insight into SUCNR1 (GPR91) structure and function
Julie Gilissen, François Jouret, Bernard Pirotte, et al.
Nature Reviews. Endocrinology
|
October 27, 2018
The causes and consequences of pituitary gigantism
Albert Beckers, Patrick Petrossians, Julien Hanson, et al.
Current Pharmaceutical Design
|
March 15, 2006
Coxibs and cardiovascular side-effects: from light to shadow
Jean-Michel Dogné, Julien Hanson, Claudiu Supuran, et al.
Biochemical Pharmacology
|
May 7, 2013
Heterologously expressed formyl peptide receptor 2 (FPR2/ALX) does not respond to lipoxin A₄
Julien Hanson, Nerea Ferreirós, Bernard Pirotte, et al.
Biochemical Pharmacology
|
December 27, 2023
Basal interaction of the orphan receptor GPR101 with arrestins leads to constitutive internalization
Dayana Abboud, Clauda Abboud, Asuka Inoue, et al.
Fundamental & Clinical Pharmacology
|
June 29, 2022
Receptor density influences the recruitment bias of aripiprazole and brexpiprazole at the dopamine D<sub>2L</sub> receptor
Mattia Ferraiolo, Romane Ponthot, Hicham Atik, et al.
Neuropharmacology
|
January 13, 2022
Dopamine D<sub>2</sub>L receptor density influences the recruitment of β-arrestin2 and G<sub>i</sub>1 induced by antiparkinsonian drugs
Mattia Ferraiolo, Hicham Atik, Romane Ponthot, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 67) with videos related to
Sort By:
Page
of 7
Trends in Pharmacological Sciences
|
October 26, 2005
Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis
Jean-Michel Dogné, Julien Hanson, Domenico Pratico
Future Medicinal Chemistry
|
May 10, 2022
Super-conserved receptors expressed in the brain: biology and medicinal chemistry efforts
Alp Bayrak, Julien Hanson, Stefan Laufer, et al.
Trends in Pharmacological Sciences
|
September 28, 2011
Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials
Martina Lukasova, Julien Hanson, Sorin Tunaru, et al.
Pharmacology & Therapeutics
|
January 26, 2016
Insight into SUCNR1 (GPR91) structure and function
Julie Gilissen, François Jouret, Bernard Pirotte, et al.
Nature Reviews. Endocrinology
|
October 27, 2018
The causes and consequences of pituitary gigantism
Albert Beckers, Patrick Petrossians, Julien Hanson, et al.
Current Pharmaceutical Design
|
March 15, 2006
Coxibs and cardiovascular side-effects: from light to shadow
Jean-Michel Dogné, Julien Hanson, Claudiu Supuran, et al.
Biochemical Pharmacology
|
May 7, 2013
Heterologously expressed formyl peptide receptor 2 (FPR2/ALX) does not respond to lipoxin A₄
Julien Hanson, Nerea Ferreirós, Bernard Pirotte, et al.
Biochemical Pharmacology
|
December 27, 2023
Basal interaction of the orphan receptor GPR101 with arrestins leads to constitutive internalization
Dayana Abboud, Clauda Abboud, Asuka Inoue, et al.
Fundamental & Clinical Pharmacology
|
June 29, 2022
Receptor density influences the recruitment bias of aripiprazole and brexpiprazole at the dopamine D<sub>2L</sub> receptor
Mattia Ferraiolo, Romane Ponthot, Hicham Atik, et al.
Neuropharmacology
|
January 13, 2022
Dopamine D<sub>2</sub>L receptor density influences the recruitment of β-arrestin2 and G<sub>i</sub>1 induced by antiparkinsonian drugs
Mattia Ferraiolo, Hicham Atik, Romane Ponthot, et al.
Page
of 7